Society Letters Society Letters

Endocrine Society Comments on DMEPOS Competitive Bidding Program Updates

August 28, 2025

To Mehmet Oz, MD, Administrator, Centers for Medicare & Medicaid Services

On behalf of the Endocrine Society, thank you for the opportunity to submit these comments on the Calendar Year (CY) 2026 Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Competitive Bidding Program Updates proposed rule. We are submitting comments specifically on the proposal to add continuous glucose monitors (CGMs) and insulin pumps to the DME competitive bidding program (CBP).

Founded in 1916, the Endocrine Society represents approximately 18,000 physicians and scientists engaged in the treatment and research of endocrine disorders, such as diabetes, hypertension, obesity, osteoporosis, endocrine cancers (i.e., thyroid, adrenal, ovarian, pituitary) and thyroid disease. Our members are leaders in the treatment of diabetes and have authored clinical practice guidelines in diabetes technology, diabetes and pregnancy, and the treatment of diabetes in older adults. As such, our members are knowledgeable about the challenges patients with diabetes face controlling their condition and have found that diverse types of diabetes technology have significantly improved their health outcomes and quality of life.

Payment for Continuous Glucose Monitors and Insulin Infusion Pumps:

The Endocrine Society appreciates the agency’s efforts to address the rapid pace of technological advancement in CGMs, and insulin pumps and shares the Agency’s goal of ensuring that beneficiaries have access to the most current technology available. As you know, diabetes technology has seen rapid advancements in recent years, and our members want to ensure that their patients have the most appropriate technology to manage their chronic disease. However, we are concerned that this proposal could result in unintended consequences which may hinder patient access and affordability. Given our concerns, we urge the agency not to finalize this proposal for these devices because of the impact this could have on prescribing decisions, patient choice, and physician administrative burden, which are outlined below.

arrow Read the Full Letter

Last Updated:
Back to top

Who We Are

For 100 years, the Endocrine Society has been at the forefront of hormone science and public health. Read about our history and how we continue to serve the endocrine community.